Google’s Verily and GlaxoSmithKline hatch a $713M plan to spark a biorevolution
Global pharma giant GlaxoSmithKline is teaming up with Google’s life sciences venture Verily, channeling its four-year effort to create new nanotech-based bioelectronic therapeutics into a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.